APA (7th ed.) Citation

Dimopoulos, M. A., & Goldschmidt, H. (2016). Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): A randomised, phase 3, open-label, multicentre study. The lancet. Oncology, 17(1), . https://doi.org/10.1016/S1470-2045(15)00464-7

Chicago Style (17th ed.) Citation

Dimopoulos, Meletios A., and Hartmut Goldschmidt. "Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma (ENDEAVOR): A Randomised, Phase 3, Open-label, Multicentre Study." The Lancet. Oncology 17, no. 1 (2016). https://doi.org/10.1016/S1470-2045(15)00464-7.

MLA (9th ed.) Citation

Dimopoulos, Meletios A., and Hartmut Goldschmidt. "Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma (ENDEAVOR): A Randomised, Phase 3, Open-label, Multicentre Study." The Lancet. Oncology, vol. 17, no. 1, 2016, https://doi.org/10.1016/S1470-2045(15)00464-7.